in intermediate risk papillary thyroid cancer (PTC) and low risk, minimally invasive follicular thyroid cancer (FTC). A higher survival rate after undergoing radioiodine therapy begins to emerge ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

There are essential differences between medullary thyroid cancer and the papillary and follicular types ... When the cancer is confined to the thyroid, the 10-year survival rate is around 90%. When it ...

Differentiated thyroid cancer patients who receive radioiodine (RAI) treatment after surgery have increased relative ...

TAR-200 demonstrated a high disease-free survival and bladder preservation rates in BCG-unresponsive, high-risk ...

The ongoing phase 2b SunRISe-1 study is assessing TAR-200 intravesical gemcitabine delivery in patients with BCG-unresponsive high-risk NMIBC.

Lymph node metastasis was uncommon among clinically node-negative PTC patients without evidence of nodal involvement on USG and CT.

A new study led by researchers at Yale University published in Environmental Health Perspectives, suggests that early-life ...

Anktiva plus BCG aims to treat BCG-unresponsive NMIBC with papillary disease, potentially reducing radical cystectomy need. The treatment showed high rates ... survival: the time after treatment that ...

Differentiated thyroid cancer patients who receive radioiodine (RAI) treatment after surgery have increased relative survival ...